Intravitreal triamcinolone acetonide for exudative age-related macular degeneration among Japanese patients

Ophthalmologica

Volumn 220, Issue 2, 2006, Pages 118-124

  Ito, Motoko ^a   Okubo, Akiko ^a   Sonoda, Yasushi ^a   Yamakiri, Keita ^a   Sakamoto, Taiji ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Age related macular degeneration; Choroidal neovascularization; Endophthalmitis; Intraocular pressure; Triamcinolone acetonide

Indexed keywords

ANTIGLAUCOMA AGENT; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE;

AGED; ARTICLE; ASIAN; CATARACT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EXUDATE; FEMALE; HUMAN; INTRAOCULAR HYPERTENSION; JAPAN; MALE; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PROBABILITY; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; EXUDATES AND TRANSUDATES; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; FUNDUS OCULI; GLUCOCORTICOIDS; HUMANS; INJECTIONS; INTRAOCULAR PRESSURE; MACULAR DEGENERATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TRIAMCINOLONE ACETONIDE; VISUAL ACUITY; VITREOUS BODY;

EID: 33344472567     PISSN: 00303755     EISSN: None     Source Type: Journal    
DOI: 10.1159/000090577     Document Type: Article

References (20)

1. Klein R, Klein BE, Linton KL: Prevalence of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology 1992;99:933-943.
2. Vingerling JR, Dielemans I, Hofman A, Grobbee DE, Hijmering M, Kramer CF, de Jong PT: The prevalence of age-related maculopathy in the Rotterdam Study. Ophthalmology 1995;102:205-210.
3. Frank RN, Puklin JE, Stock C, Canter LA: Race, iris color, and age-related macular degeneration. Trans Am Ophthalmol Soc 2000;98:109-115.
4. Katz J, Bressler NM, Rahmani B, Tielsch J: Racial differences in the prevalence of age-related macular degeneration: the Baltimore Eye Survey. Ophthalmology 1999;106:1049-1055.
5. Miyazaki M, Nakamura H, Kubo M, Kiyohara Y, Oshima Y, Ishibashi T, Nose Y: Risk factors for age related maculopathy in a Japanese population: the Hisayama study. Br J Ophthalmol 2003;87:469-472.
6. Pauleikhoff D, Koch JM: Prevalence of age-related macular degeneration. Curr Opin Ophthalmol 1995;6:51-56.
7. The Japanese Age-Related Macular Degeneration Trial (JAT) study group: Japanese age-related macular degeneration trial: 1-year results of photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Am J Ophthalmol 2003;136:1049-1061.
8. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) study group: Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP report. Arch Ophthalmol 1999;117: 1329-1345.
9. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) study group: Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials - TAP report 2. Arch Ophthalmol 2001;119: 198-207.
10. Danis RP, Ciulla TA, Pratt LM, Anliker W: Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 2000;20:244-250.
11. Gillies MC, Simpson JM, Billson FA, Luo W, Penfold P, Chua W, Mitchell P, Zhu M, Hunyor ABL: Safety of an intravitreal injection of triamcinolone. Arch Ophthalmol 2004;122: 336-340.
12. Gillies MC, Simpson JM, Luo W, Penfold P, Hunyor ABL, Chua W, Mitchell P, Billson F: A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration. Arch Ophthalmol 2003;121:667-673.
13. Jonas JB, Kreissig I, Hugger P, Sauder G, Panda-Jonas S, Degenring R: Intravitreal triamcinolone acetonide for exudative age related macular degeneration. Br J Ophthalmol 2003;87:462-468.
14. Ranson NT, Danis RP, Ciulla TA, Pratt L: Intravitreal triamcinolone in subfoveal recurrence of choroidal neovascularisation after laser treatment in macular degeneration. Br J Ophthalmol 2002;86:527-529.
15. Jonas JB, Kreissig I, Degenring R: Intraocular pressure after intravitreal injection of triamcinolone. Br J Ophthalmol 2003;87:24-27.
16. Moshfeghi DM, Kaiser PK, Scott IU, Sears JE, Benz M, Sinesterra JP, Kaiser RS, Bakri SJ, Maturi RK, Belmont J, Beer PM, Murray TG, Quiroz-Mercado H, Mieler WF: Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol 2003;136:791-796.
17. Roth DB, Cheieh J, Spirn MJ, Green SN, Yarian DL, Chaudhry NA: Noninfectious endophthalmitis associated with intravitreal triamcinolone injection. Arch Ophthalmol 2003;121: 1279-1282.
18. Jonas JB, Kreissig I, Degenring RF: Endophthalmitis after intravitreal injection of triamcinolone acetonide. Arch Ophthalmol 2003;121:1663-1664.
19. Parke DW: Intravitreal triamcinolone and endophthalmitis. Am J Ophthalmol 2003;136: 918-919.
20. Sakamoto T, Enaida H, Kubota T, Nakahara M, Yamakiri K, Yamashita T, Yokoyama M, Hata Y, Murata T, Miyata K, Uemura A, Kimura W, Ishibashi T: Incidence of acute endophthalmitis after triamcinolone-assisted pars plana vitrectomy. Am J Ophthalmol 2004;138:137-138.